PRAVASTATIN SODIUM (pravastatin sodium) by Ichnos Glenmark Innovation is hmg-coa reductase, the rate-limiting enzyme that converts hmg-coa to mevalonate, a precursor of cholesterol. Approved for clinically evident chd. First approved in 2007.
Drug data last refreshed 10h ago
HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a precursor of cholesterol.
Pravastatin Sodium 80 mg Tablets Under Fasting Conditions
Fed, Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Subjects
Fasting Bioequivalence Study of Pravastatin Sodium 80 mg Tablets Versus Pravachol® 80 mg Tablets In Normal Healthy Subjects
Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fasting Conditions
Bioequivalence Study of Pravastatin Sodium Tablets 80 mg Under Fed Conditions
Worked on PRAVASTATIN SODIUM at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.